BR112015023060A2 - entidades químicas - Google Patents
entidades químicasInfo
- Publication number
- BR112015023060A2 BR112015023060A2 BR112015023060A BR112015023060A BR112015023060A2 BR 112015023060 A2 BR112015023060 A2 BR 112015023060A2 BR 112015023060 A BR112015023060 A BR 112015023060A BR 112015023060 A BR112015023060 A BR 112015023060A BR 112015023060 A2 BR112015023060 A2 BR 112015023060A2
- Authority
- BR
- Brazil
- Prior art keywords
- chemical entities
- compositions
- treatment
- œchemical
- entitiesâ
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
Abstract
resumo da patente de invenã§ã£o para: âentidades quãmicasâ. sã£o fornecidas entidades quãmicas selecionadas a partir de compostos de fã³rmula (i), em que r1, r2 e m tãªm os significados indicados na descriã§ã£o, e os sais, solvatos e estereoisã´meros farmaceuticamente aceitã¡veis dos mesmos, que sã£o inibidores de atr e sã£o potencialmente ãºteis no tratamento de cã¢ncer. sã£o ainda proporcionadas composiã§ãµes farmacãªuticas das entidades quãmicas, produtos de combinaã§ã£o que contãªm as entidades quãmicas, uso das composiã§ãµes como agentes terapãªuticos, e mã©todos de tratamento utilizando essas composiã§ãµes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13382089 | 2013-03-15 | ||
EP13382089.4 | 2013-03-15 | ||
PCT/GB2014/050825 WO2014140644A1 (en) | 2013-03-15 | 2014-03-14 | Chemical entities |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015023060A2 true BR112015023060A2 (pt) | 2017-07-18 |
BR112015023060B1 BR112015023060B1 (pt) | 2022-07-05 |
Family
ID=48013903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015023060-1A BR112015023060B1 (pt) | 2013-03-15 | 2014-03-14 | Entidades químicas |
Country Status (32)
Country | Link |
---|---|
US (1) | US9453031B2 (pt) |
EP (1) | EP2970332B1 (pt) |
JP (1) | JP6379115B2 (pt) |
KR (1) | KR102206318B1 (pt) |
CN (1) | CN105051047B (pt) |
AR (1) | AR095443A1 (pt) |
AU (1) | AU2014229735B2 (pt) |
BR (1) | BR112015023060B1 (pt) |
CA (1) | CA2904768C (pt) |
CL (1) | CL2015002591A1 (pt) |
CY (1) | CY1120619T1 (pt) |
DK (1) | DK2970332T3 (pt) |
EA (1) | EA029771B1 (pt) |
ES (1) | ES2670674T3 (pt) |
HK (1) | HK1215021A1 (pt) |
HR (1) | HRP20180839T1 (pt) |
HU (1) | HUE037685T2 (pt) |
IL (1) | IL240708B (pt) |
LT (1) | LT2970332T (pt) |
MX (1) | MX368056B (pt) |
NO (1) | NO2970332T3 (pt) |
NZ (1) | NZ711038A (pt) |
PE (1) | PE20152007A1 (pt) |
PH (1) | PH12015502159B1 (pt) |
PL (1) | PL2970332T3 (pt) |
PT (1) | PT2970332T (pt) |
RS (1) | RS57216B1 (pt) |
SG (1) | SG11201507555PA (pt) |
SI (1) | SI2970332T1 (pt) |
TW (1) | TWI557131B (pt) |
UA (1) | UA118261C2 (pt) |
WO (1) | WO2014140644A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
BR112015016793B1 (pt) | 2013-01-15 | 2021-12-28 | Incyte Holdings Corporation | Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos |
US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016112374A2 (en) * | 2015-01-09 | 2016-07-14 | The General Hospital Corporation | Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr) |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
CN109071565B (zh) * | 2016-05-24 | 2022-05-10 | 默克专利股份公司 | 三环杂环衍生物 |
TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
AU2019217388C1 (en) * | 2018-02-07 | 2024-03-07 | Wuxi Biocity Biopharmaceutics Co., Ltd. | ATR inhibitor and application thereof |
WO2020094084A1 (zh) * | 2018-11-07 | 2020-05-14 | 南京明德新药研发有限公司 | 作为ret抑制剂的三并环衍生物 |
CN113004303A (zh) * | 2019-12-18 | 2021-06-22 | 江苏恒瑞医药股份有限公司 | 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用 |
WO2021143821A1 (zh) * | 2020-01-17 | 2021-07-22 | 江苏恒瑞医药股份有限公司 | 稠合杂芳基类衍生物、其制备方法及其在医药上的应用 |
JP2023545196A (ja) | 2020-10-16 | 2023-10-26 | シャンハイ ドーァ ノボ ファーマテック カンパニー,リミティド | 三複素環誘導体、その医薬組成物及び使用 |
CN115466258A (zh) * | 2021-06-11 | 2022-12-13 | 成都苑东生物制药股份有限公司 | Atr抑制剂及其用途 |
CN115286645A (zh) * | 2022-08-16 | 2022-11-04 | 南京雷正医药科技有限公司 | 三环杂环衍生物及其药物组合物和用途 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
WO1993014080A1 (en) * | 1992-01-15 | 1993-07-22 | E.I. Du Pont De Nemours And Company | Bridged heterocyclic fungicides |
JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
US20020192228A1 (en) | 1997-02-12 | 2002-12-19 | Samir M. Hanash | Protein markers for lung cancer and use thereof |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
PL199802B1 (pl) | 1999-02-10 | 2008-10-31 | Astrazeneca Ab | Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania |
EP1676845B1 (en) | 1999-11-05 | 2008-06-11 | AstraZeneca AB | New quinazoline derivatives |
ES2290117T3 (es) | 2000-02-15 | 2008-02-16 | Sugen, Inc. | Inhibidores de proteina quinasa 2-indolina sustituida con pirrol. |
IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
KR20030022264A (ko) | 2000-07-07 | 2003-03-15 | 앤지오젠 파마슈티칼스 리미티드 | 신생 혈관 형성 억제제인 콜치놀 유도체 |
US20050277627A1 (en) | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
US8735411B2 (en) * | 2006-10-02 | 2014-05-27 | Abbvie Inc. | Macrocyclic benzofused pyrimidine derivatives |
KR20090085591A (ko) * | 2006-10-30 | 2009-08-07 | 노파르티스 아게 | Pi3k 지질 키나제 억제제로서의 이미다조피리다진 |
PE20090215A1 (es) * | 2007-05-09 | 2009-03-30 | Novartis Ag | Compuestos derivados de imidazopiridazinas como inhibidores de cinasa |
JP5746172B2 (ja) * | 2009-08-20 | 2015-07-08 | カルス セラピューティクス リミテッド | ホスホイノシチド3−キナーゼ阻害剤としての三環式複素環化合物 |
CN102020657A (zh) * | 2009-09-11 | 2011-04-20 | 上海艾力斯医药科技有限公司 | 稠合杂芳基衍生物、制备方法及其应用 |
CA2803802A1 (en) * | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
BR112013014914B8 (pt) | 2010-12-16 | 2020-08-04 | Hoffmann La Roche | composto, composição farmacêutica e uso de um composto |
-
2014
- 2014-03-13 AR ARP140100990A patent/AR095443A1/es unknown
- 2014-03-14 NO NO14716910A patent/NO2970332T3/no unknown
- 2014-03-14 PT PT147169106T patent/PT2970332T/pt unknown
- 2014-03-14 EP EP14716910.6A patent/EP2970332B1/en active Active
- 2014-03-14 CN CN201480015613.0A patent/CN105051047B/zh active Active
- 2014-03-14 PL PL14716910T patent/PL2970332T3/pl unknown
- 2014-03-14 HU HUE14716910A patent/HUE037685T2/hu unknown
- 2014-03-14 CA CA2904768A patent/CA2904768C/en active Active
- 2014-03-14 RS RS20180576A patent/RS57216B1/sr unknown
- 2014-03-14 AU AU2014229735A patent/AU2014229735B2/en active Active
- 2014-03-14 WO PCT/GB2014/050825 patent/WO2014140644A1/en active Application Filing
- 2014-03-14 UA UAA201510054A patent/UA118261C2/uk unknown
- 2014-03-14 SG SG11201507555PA patent/SG11201507555PA/en unknown
- 2014-03-14 ES ES14716910.6T patent/ES2670674T3/es active Active
- 2014-03-14 US US14/774,294 patent/US9453031B2/en active Active
- 2014-03-14 NZ NZ711038A patent/NZ711038A/en unknown
- 2014-03-14 BR BR112015023060-1A patent/BR112015023060B1/pt active IP Right Grant
- 2014-03-14 DK DK14716910.6T patent/DK2970332T3/en active
- 2014-03-14 EA EA201591781A patent/EA029771B1/ru not_active IP Right Cessation
- 2014-03-14 JP JP2015562337A patent/JP6379115B2/ja active Active
- 2014-03-14 PE PE2015001900A patent/PE20152007A1/es active IP Right Grant
- 2014-03-14 TW TW103109396A patent/TWI557131B/zh active
- 2014-03-14 SI SI201430698T patent/SI2970332T1/en unknown
- 2014-03-14 LT LTEP14716910.6T patent/LT2970332T/lt unknown
- 2014-03-14 MX MX2015011549A patent/MX368056B/es active IP Right Grant
- 2014-03-14 KR KR1020157025265A patent/KR102206318B1/ko active IP Right Grant
-
2015
- 2015-08-20 IL IL240708A patent/IL240708B/en active IP Right Grant
- 2015-09-10 CL CL2015002591A patent/CL2015002591A1/es unknown
- 2015-09-15 PH PH12015502159A patent/PH12015502159B1/en unknown
-
2016
- 2016-03-14 HK HK16102921.2A patent/HK1215021A1/zh unknown
-
2018
- 2018-05-24 CY CY181100555T patent/CY1120619T1/el unknown
- 2018-05-25 HR HRP20180839TT patent/HRP20180839T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015023060A2 (pt) | entidades químicas | |
UY33440A (es) | ?compuestos pirimidinílicos para uso como inhibidores de atr?. | |
BR112015011147A8 (pt) | composto, composição farmacêutica, e, uso do referido composto | |
UY31918A (es) | Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento | |
BR112015014585A2 (pt) | composto, composição farmacêutica, e, método de tratamento de um ser humano | |
NI201000004A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
CR11200A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k | |
BR112015011148A8 (pt) | composto, composição farmacêutica, e combinação | |
UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
ECSP109934A (es) | Compuesto - 946 | |
UY35684A (es) | Formulación de inhibidores de la tirosina quinasa de bazo (syk) | |
UY32351A (es) | Compuestos de pirimidinil indol para uso como inhibidores de atr | |
BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
BR112015024050A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BR112015023891A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BR112017004589A2 (pt) | composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd | |
BR112015023858A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
AR093851A1 (es) | Metodos para tratar la diabetes administrando un antagonista del receptor de glucagon en combinacion con un inhibidor de la absorcion del colesterol, combinacion | |
BR112015014855A2 (pt) | compostos radiossensibilizadores para uso em combinação com radiação | |
BR112015005392A2 (pt) | formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase | |
BR112017003881A2 (pt) | derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak | |
BR112017003880A2 (pt) | derivados de poliéteres de n-aril-triciclopirimidina-2-amina macrocíclicos como inibidores de ftl3 e jak | |
CU20160018A7 (es) | Composiciones farmacéuticas de compuestos que inhiben la actividadde tirosina cinasa y sus métodos de preparación | |
GT201500189A (es) | Inhibidores de autotaxina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS |